Dataset from Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)

Primary Outcome Measures:

The primary endpoint was the time to onset of symptom relief of the first attack in the
double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic
acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid
refers to the hazard rate under tranexamic acid.

Secondary Outcome Measures:

- Additional efficacy assessments (Time to Almost Complete Symptom Relief)

- Safety and tolerability

- Pharmacoeconomics